North America Human Microbiome Market Size, Share & Growth
The North America Human Microbiome market, valued at US$0.43 billion in 2024, stood at US$0.78 billion in 2025 and is projected to advance at a resilient CAGR of 32.2% from 2025 to 2031, culminating in a forecasted valuation of US$4.15 billion by the end of the period.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=268083046
The North America human microbiome market growth is driven by improvements in novel microbiome-based products and therapeutic solutions due to partnerships between industry players and academic institutions. New startups in the US and Canada are driving innovation across microbiome therapeutics and diagnostics.
- The US human microbiome market made up 86.6% of the North American market in 2024.
- Among product categories, microbiome drugs are expected to record the highest CAGR of 35.3%, largely due to a growing pipeline of microbiome-based therapeutics and greater funding for drug development.
- From a route-of-administration perspective, the rectal route is projected to grow the fastest from 2025 to 2031.
- From a disease perspective, gastrointestinal disorders dominated the market in 2024, contributing 58.4% of total market.
- Several companies stand out as key players in the North America microbiome market, including International Flavors & Fragrances Inc., Seed Health, Inc., and Seres Therapeutics, all of which have built strong market presence and extensive product portfolios.
- Among startups and SMEs, companies such as AOBiome, Vedanta Biosciences, Inc., and Synlogic are emerging as promising leaders by carving out strong positions in niche application areas.
The human microbiome market in North America keeps growing steadily owing to the collaboration among biotechnology companies, academic institutions, and clinical research centers. The partnerships drive innovation in microbiome-based products and treatments. The presence of startups and medium sized enterprises, in the region speeds up research, product development and commercialization particularly in microbiome therapeutics, diagnostics and consumer health.
